Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
11/05/2026 07:25
May 11 (Reuters) - Poolbeg Pharma PLC POLB.L: POOLBEG PHARMA PLC - GRANTED POLB 001 CANCER IMMUNOTHERAPY-INDUCED CRS PATENT IN CANADA Source text: ID:nRSK6778Da Further company coverage: POLB.L ((Reuters.Briefs@thomsonreuters.com))
Recent news on Poolbeg Pharma
See all newsBrief: Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001
Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
Annual Report & AGM Notice
Results for the year ended 31 December 2025
Appointment of Dr Adrian Kilcoyne to SAB